Despite advances in surgical and adjuvant therapy, the prognosis for malignant gliomas remains dismal. This gloomy scenario has been recently brightened by the increasing understanding of the genetic and biological mechanisms at the basis of brain tumor development. These findings are being translated into innovative therapeutic approaches, including gene therapy, virotherapy, and vaccination, some of which have already been experimented in clinical trials. The advantages and disadvantages of all these different therapeutic modalities for malignant gliomas will be critically discussed, providing perspective for future investigations.
Introduction
Malignant gliomas remain among the mostly lethal cancers in humans, with an overall incidence of about 3 per 100 000 people per year 1 and a median survival of less than 1 year. 2 Standard treatment consists of surgery followed by radiotherapy and sometimes adjuvant chemotherapy. Eventually almost all malignant gliomas recur and, at recurrence, the median survival is 2-3 months. 2 The reason for the failure of conventional therapy is inherent to the intrinsic biological properties of malignant glioma cells, which are highly infiltrative into the brain, thus preventing total tumor resection, and resistant to chemotherapy and radiotherapy. Thus, the goal of novel treatment strategies for malignant gliomas should be twofold: improvement of tumor debulking and enhancement of tumor cell killing. These aims have been pursued by gene therapy, virotherapy, adoptive immunotherapy, and vaccination studies, which have been translated into several clinical trials. Although the results -in terms of tumor response -achieved so far from clinical trials are still rather poor, a positive remark derives from the tolerability and safety of treatment that has been demonstrated in almost all studies. It should however be noted that the majority of clinical studies were pilot or phase I protocols aiming at assessing the feasibility and safety of treatment, rather than efficacy. This review article focuses on the results from these clinical trials, with particular emphasis on the most promising achievements, which should be kept as the basis for further investigations and for the design of controlled phase II and III studies.
Gene therapy approaches
More than a decade has elapsed since the first clinical study of gene therapy for patients with malignant gliomas 3 and more than 40 trials have been approved since then (Figure 1 ). Gene transfer techniques to the brain have been generally based on the direct injection of the gene transfer vector or vector producer cells (VPCs) into the tumor mass or into the surgical cavity margin after tumor debulking. The most frequently used therapeutic genes in clinical trials include prodrug activating genes (suicide genes) and cytokine genes, and, less frequently, tumor suppressor genes (e.g., TP53). Results are now available from several clinical trials. Unfortunately, they are rather disappointing in terms of clinical response, even though treatment procedures and gene transfer have been generally proven to be safe and well tolerated 4, 5 (Table 1) . Reasons for such failure have been mainly ascribed to inefficient transduction of target tumor cells (as reported for other types of cancers), rather than to the gene therapy strategy per se.
Gene transfer vectors
In gene therapy clinical trials for malignant gliomas, genes are generally delivered by means of retroviral vectors or adenoviral vectors, though nonviral vectors (liposomes) are also employed. Viral vectors. Retroviral vectors -As for retroviral vectors, Moloney-derived retroviral vectors are generally used and administered to the patient by direct injection of murine retroviral vector-producing cells (RVPCs) ( Table 1 ). The rationale for using retroviral vectors is based on their property to transduce only dividing cells, such as glioblastoma cells, and thus to spare neurons, which are typically resting cells. Transduction rate achieved in vivo by intratumor RVPC injection is however rather low, and estimated to be below 0.002 11 or 0.03% 25 in two different clinical studies. Transduction efficacy could probably be improved, since much higher transduction rates have been reported in animal models of glioma 26 and of other types of cancer. 27 Inefficient transduction in humans seems to be mainly due to rapid inactivation of free retroviral vectors by complement and due to lack of dissemination of RVPCs away from the injection sites. On the other hand, the positive aspect of retroviral vectors is lack of significant side effects, with doses up to 1 Â 10 9 RVPCs in a total volume of 10 ml. No replication-competent retroviral vectors have been ever demonstrated, although transduction of circulating cells by vectors may occur. 6, 8, 9, 14, 24, 28 The risk of cancer due to insertional mutagenesis cannot be excluded in patients treated with retroviral vectors. However, the presence of the herpes simplex virus type 1 (HSV-TK) gene in transduced cells allows to eliminate, by ganciclovir (GCV) treatment, any cell that may have undergone transformation.
Adenoviral vectors -First-generation E1-deleted adenoviral vectors have been used more recently in gene therapy clinical trials for malignant gliomas (Table 1) . At variance with retroviral vectors, which are administered through RVPCs because of their low titer, adenoviral vectors can be directly injected into the target site at high titer. In patients with gliomas, adenoviral vectors have been injected at doses up to 3 Â 10 12 viral particles (vp) into the tumor mass or into the surgical cavity after tumor resection. However, at such high doses, their delivery may lead to severe side effects. In fact, phase I dose escalation trials showed that doses of 10 12 vp may be accompanied by severe toxicity, with CNS symptoms, fever, leukocytosis, and hyponatremia, 10 whereas lower doses are well tolerated. 10, 16, 19, 22 Toxicities associated with adenoviral vectors are generally consistent with a transient inflammatory response to the vector, as observed in other clinical trials with this type of vectors. 4 On the other hand, cellular and humoral immune response elicited by adenoviral vectors undoubtedly contributes to the antitumor activity of gene therapy, even though the antibody response against adenoviral vectors, which can pre-exist in the host or develop after treatment, even in the case of intracerebral injection, could interfere with vector delivery. 10, 19 Adenoviral vectors can transduce both dividing and nondividing cells and are therefore more efficient than retroviral vectors against tumors with low mitotic index. In the site of vector injection, 95-100% of cells are transduced and express the transgene, but transduced cells reside within only a short distance from the injection site, with a mean maximal distance of about 5 mm. 19 Replication-competent adenoviral vectors have never been detected in any biological sample from glioma patients as well as from patients with other types of malignancies treated with adenoviral vector injection, 10, 16, 19, 22 even though vector sequences may be transiently detected in the peripheral blood shortly after gene therapy. 22 Nonviral vectors. Nonviral vectors, such as cationic liposomes, have the advantages of low immunogenicity and toxicity, easy manufacturing, and long-term stability. Cationic liposomes have been used to deliver the suicide gene thymidine kinase of HSV-TK to eight patients with GBM. 20, 21 The liposome-DNA complex was administered by convection-enhanced delivery through catheters stereotactically implanted into the tumor and transcutaneously linked to an external pump. 21 Vector infusion was accompanied by transient worsening of neurological symptoms, fever, and increase of transaminase levels. Expression of the HSV-TK gene could be monitored by positron emission tomography (PET) after intravenous administration of [ 124 I]FIAU (I-124-labeled 2 0 -fluoro-2 0 -deoxy-1b-D-arabino-furanosyl-5-iodo-uracil), a specific substrate for HSV-TK. Specific accumulation of FIAU was detected at the infusion site in one of the patients, in whom the greatest density of recurrent tumor cells had been documented histologically. In this patient, PET scans also showed the appearance of signs of local tumor necrosis after treatment with GCV. 20 Thus, also the results of this clinical trial with liposome vectors showed that the therapeutic effect was restricted to a relatively small volume around the infusion site; 21 notwithstanding, a convection-enhanced delivery technique was used, which should allow delivery of molecules inside brain tissue over long distances. 29 
Methods for gene delivery
The surgical techniques employed for vector delivery to brain tumors consist of direct injection of the vectors 30 Its principal shortcomings are the lack of a debulking effect with no immediate improvement on mass effect. Injection of vectors or VPCs after surgical removal of the tumor mass allows an accurate haemostasis control under microscopic vision and reduces the risk of injection into the ventricles and CSF spaces. The number of injection sites and the volume of injected material can be increased, but, using visual control alone, planning of injections is forcibly less accurate, even when targeted to evident residual tumor.
Gene therapy strategies
Tumor suppressor gene replacement. Based on the observation that inactivation of the TP53 tumor suppressor gene represents a critical event in the pathogenesis of malignant gliomas and that transfer of TP53 in animal models inhibited growth of gliomas and restored their sensitivity to radiotherapy and chemotherapy, a phase I clinical trial of TP53 adenoviral vector-mediated gene therapy was undertaken in patients with recurrent malignant gliomas 19 (Table 1 ). In this study, patients underwent intratumor stereotactic injection of the Ad-p53 adenoviral vector via an implanted catheter, followed by en bloc resection for analysis and treatment of the postresection cavity. Of 15 patients enrolled, 12 underwent both treatment stages and could be evaluated for clinical toxicity and transduction efficiency. Toxicity of gene therapy was minimal and a maximum tolerated dose was not reached. Moreover, no systemic viral dissemination was observed. Analysis of tumor specimens showed expression of p53 protein within the nuclei of glioma cells, but transduced cells were only found within a short distance of the injection site. This is an important limitation, since the requirement for the success of tumor suppressor gene therapy is efficient transduction of the whole population of tumor cells. Due to the design of the study, tumor response could not be assessed.
Prodrug/suicide gene therapy. Most gene therapy clinical trials for malignant gliomas have been based on the delivery of the suicide gene HSV-TK, followed by GCV administration (Table 1 ) (for a detailed review on HSV-TK-based clinical trials on malignant gliomas, see Pulkkanen and Yla-Herttuala ). The HSV-TK enzyme phosphorylates the prodrug GCV into the active compound GCV triphosphate, an inhibitor of DNA synthesis that leads to cell death. A useful feature of HSV-TK/GCV gene therapy is the 'bystander effect', that is, killing of nontransduced neighbor cells by GCV treatment. This effect is mediated by transfer of toxic metabolites and by stimulation of an immune response involving tumor infiltrating T cells and natural killer (NK) cells. 31 Notwithstanding the presence of the bystander effect, this gene therapy approach gave poor results not only in patients with malignant gliomas but also in patients with other types of cancer. 4 With a few anecdotal exceptions, lack of efficacy was particularly observed in clinical trials based on the use of RVPCs as gene transfer tools. 5 In a total of 79 evaluable patients with recurrent GBM enrolled in nine phase I/II studies of retroviral vectormediated HSV-TK gene therapy, complete or partial responses were observed in 13% of cases, and minor responses or stable disease in 18% (Table 1) . In most studies, treatment consisted in injection of RVPCs into the surgical cavity after tumor debulking and not in direct intratumor injection of the RVPCs. Therefore, response to treatment was difficult to assess. In the studies of HSV-TK gene therapy based on intratumor injection of RVPCs, 5, 7 tumor regression was observed in a relatively high percentage of patients, especially in those with small tumor recurrences. Unfortunately, tumor responses were limited to the site of RVPC injection, whereas untreated tumor masses progressed rapidly. 7 Lack of efficacy of retroviral vector-mediated HSV-TK/GCV gene therapy after tumor debulking was confirmed by a phase III clinical trial, which showed no significant benefit of gene therapy over radiotherapy in newly diagnosed patients with GBM. 14 In this study, patients underwent gross surgical resection of the tumor and radiotherapy. In the gene therapy arm, 124 patients were treated by RVPC injection into the wall of the resection cavity, followed by intravenous GCV infusion, whereas the 124 patients of the control arm were treated only by surgery and radiotherapy. Besides the lack of efficacy of gene therapy, this study showed a higher rate of side effects, including cranial hematomas and thromboembolic events, in the gene therapy arm than in controls.
14 Of note, this trial allowed the investigation of the immunological component of HSV-TK/GCV gene therapy. 32 Serum samples from treated patients showed in fact increased FasL and interleukin (IL)-12 levels, 14 consistent with activation of a Th-1 response. A similar response was observed in an adolescent patient with ependymoma after intracranial implantation of HSV-TK RVPCs. 33 Moreover, peripheral blood mononuclear cells cocultivated with autologous tumor cells or with RVPCs demonstrated a transient (days 7-28 after RVPC injection) but specific-T1-type immune response. 32 Development of an immune response against retroviral vector proteins and RVPCs has also been demonstrated. 7, 9 Adenoviral vectors have been more recently investigated for gene therapy of malignant gliomas. 13, 16, 18, 19, 22 A randomized, controlled study of adenovirus-mediated HSV-TK gene therapy in patients with operable primary or recurrent malignant gliomas demonstrated a significant longer survival time in patients treated with standard therapy plus HSV-TK/GCV gene therapy than to control patients receiving only standard treatment. 22 A previous report by the same authors, 13 which compared the safety and efficacy of adenovirus-vs RVPC-mediated HSV-TK gene therapy for patients with malignant glioma, showed that both treatments were well tolerated, but that the mean survival for the adenoviral vector-treated group was superior to that for patients treated with RVPCs. Based on the results of these studies, gene therapy clinical protocols based on RVPC injection have been generally replaced by the use of adenoviral vectors.
Suicide/cytokine gene therapy. In order to amplify the antitumor immune response elicited by HSV-TK/GCV, combined delivery of the suicide gene together with the human IL-2 gene by means of a retroviral vector has been attempted in patients with recurrent GBM. 23, 24 Treatment was well tolerated and adverse events were generally mild and mainly related to GCV administration, such as transient elevation of liver function tests. As observed in HSV-TK/GCV clinical studies, also in this trial two cases of fatal pulmonary embolism were reported, which could conceivably be accounted to the increased thromboembolic risk of glioma patients, even though the contribution of the systemic activation of cytokine cascades after gene therapy could not be excluded. Regression of tumor masses was observed in 50% of cases, including the case of a patient who showed complete regression of a distant 4 ml untreated brain lesion, besides reduction of the tumor mass injected with RVPCs. In this patient, tumor response was accompanied by a marked increase of circulating Th1 cytokine levels, especially interferon (IFN)g and TNFa, immediately after RVPC injection, and a persistent cytokine hypersecretion during follow-up observation. 24 A similar profile of plasma cytokine levels was observed also in the other patients showing tumor response to treatment. Moreover, analysis of tumor biopsies obtained after injection of RVPCs demonstrated the presence of tumor necrosis around the injection site and an intense cellular infiltration, represented mainly by T-helper/inducer lymphocytes and activated cytotoxic T cells and macrophages. 23 
Oncolytic virus therapy
Limitations of replication-defective viral vectors, regarding inadequate delivery, insufficient expression of the therapeutic gene, and short-term efficacy of treatment, have been faced by the development of replicationcompetent viruses, with the ability to selectively replicate and kill cancer cells (oncolytic viruses). Once the infected cell undergoes lysis, thousands of new vp's are released and new cells are infected and killed in successive rounds of infection and cytolysis. Tumor selectivity has been achieved by using attenuated viruses that preferentially replicate in tumor cells, by inactivating viral genes that are necessary for replication in normal cells but dispensable in tumor cells in which the missing function is supplied, or by engineering viruses in which replication-essential genes are placed under tumor-specific promoters. 34 Most oncolytic viruses have been engineered from adenovirus and HSV-1, although inherently tumor-selective viruses, such as Newcastle disease virus (NDV), reovirus, and autonomous parvoviruses, are also being tested in clinical trials. Some of these vectors have been experimented in pilot and phase I clinical studies in patients with malignant gliomas (Table 2 ).
Oncolytic HSV-1 Replication-competent oncolytic HSV-1 used in clinical protocols for gliomas include G207 and HSV1716. The double-mutant G207 herpes simplex virus harbors deletions of both copies of the neurovirulence gene g34.5 and contains an insertional inactivation in the U L 39 locus, which encodes ICP6, a subunit of viral ribonucleotide reductase essential for viral replication in postmitotic cells. 35 The HSV1716 virus is similar to G207, since it lacks both copies of g34.5, but it retains a wild-type ICP6 gene. 36 Besides its essential role in HSV-1 pathogenicity in neurons, the g34.5 protein product ICP34.5 is involved in overcoming host cell defenses against infection mediated by protein kinase R (PKR). Upon infection, PKR activation shuts down translation in the infected cell by phosphorylating and inactivating eukaryotic initiation factor-2a (eIF-2a). ICP34.5 binds and recruits protein phosphatase 1-a to dephosphorylate eIF-2a, so that protein synthesis may proceed. g34.5-null viruses replicate in cells with defective PKR pathways, such as cancer cells with ras overexpression, whereas they cannot efficiently replicate in cells with a functional PKR pathway. 42 Moreover, deletions of the g34.5 gene also remove sequences encoding latency-activated transcripts and thus impair the ability of these viruses to establish latency within infected cells. 43 Inactivation of ICP6 provides further safety properties, that is, ability to replicate only in dividing cells 44 and increased sensitivity to acyclovir and GCV. 45 The G207 virus was experimented in a phase I doseescalation study in patients with recurrent malignant gliomas 35 ( Table 2 ). All patients were treated by stereotactic intratumor injection of viruses at doses up to 3 Â 10 9 pfu. No patient developed HSV encephalitis nor any other significant toxicity, besides mild neurological deterioration, and a maximally tolerated dose could not be established. Moreover, 8 of 20 patients had reduced enhancement volumes of their tumors at MRI performed 1 month after surgery as compared to the immediate postinoculation scans. Out of these patients, one showed almost complete tumor regression and three others had relatively long survival times. 35 Safety and toxicity of the HSV1716 virus were first evaluated in a phase I dose-escalation study in nine patients with recurrent high-grade glioma, who did not show any sign of encephalitis, even at the highest dose of 10 5 pfu. 36 No virus shedding was demonstrated in biological samples, nor evidence of viral genomes in tumor biopsies and post-mortem material obtained some months after treatment. As for tumor response to virotherapy, five patients had stable disease, whereas the others progressed. Efficacy of HSV1716 was evaluated in a subsequent study in 12 patients with high-grade glioma (Table 2) , who, 4-9 days after intratumor injection of the virus, underwent surgical removal of the tumors to assess viral replication. 37 Infectious HSV1716 was recovered from the resected tumors at the injection site in two cases and detected by PCR in eight other cases. Tumor tissue from one of the patients inoculated with HSV1716 was cultured in vitro and tested for the presence of the virus, with negative results. When cells were reinfected in vitro, a small fraction was found to not undergo lysis and to continue to shed the virus. 46 Thus, even though glioblastoma cells are generally fully permissive for HSV1716 lytic replication, as demonstrated in primary GBM cell cultures, 38, 47 some could support persistent viral infection and shed vp's to the surrounding tumor cells. 48 The HSV1716 virus was also used as adjuvant treatment in patients with newly diagnosed or recurrent high-grade gliomas, by injection into the brain surrounding the surgical cavity, after tumor debulking 38 ( Table 2 ). As clinically indicated, patients proceeded to further radiotherapy or chemotherapy. Of note, also in this case no toxicity related to HSV1716 administration was observed, thus confirming the safety profile of oncolytic HSV-1. Moreover, three of the 12 treated patients had a long disease-free survival, including a patient who showed tumor size reduction at follow-up imaging evaluation. 38 
Oncolytic adenoviruses
Adenoviruses carrying mutations of the early genes E1A or E1B, which are responsible for binding and inactivating several proteins involved in cell cycle control and apoptosis, such as pRB family members and p53, preferentially replicate and lyse cancer cells. ONYX-015 (dl1520), one of the first oncolytic adenoviruses to be designed, has been experimented against a variety of human cancers in phase I/II clinical trials, which demonstrated its safety and anticancer activity, especially in combination with chemo-and radiotherapy. 4, 34 ONYX-015 virus preferentially replicates in p53-deficient cells because it carries a deletion of the sequence encoding the p53-inactivating protein E1B-55K. E1B-55K is dispensable in tumor cells that are deficient for p53 function, where viral replication can proceed unimpaired. 34 A phase I dose-escalation trial of ONYX-015-based virotherapy was performed in 24 patients with recurrent malignant gliomas 39 ( Table 2 ). The virus was injected at 10 7 -10 10 pfu in a total of 10 sites within the surgical cavity after tumor resection. None of the patients experienced serious adverse events related to ONYX-015, and the maximum tolerated dose was not reached. Unfortunately, safety of treatment was not accompanied by similar positive results regarding efficacy, since all patients progressed, with the exception of a patient with anaplastic astrocytoma who had stable disease. The median time to tumor progression was 46 days and the median survival time 6.2 months. Interestingly, in two patients who underwent a second resection 3 months after ONYX-015 injection, a lymphocytic and plasmacytoid cell infiltrate was demonstrated at the site of injection. 39 Oncolytic NDV NDV is an avian paramyxovirus, which is nonpathogenic to humans, except for rare transient respiratory infection among poultry farmers. Some attenuated NDV strains have marked oncolytic properties against human tumors,
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Cancer Gene Therapy while sparing non-neoplastic cells. 49 The mechanism of the oncolytic action of attenuated NDV is still unknown, even though activation of Ras signaling pathway in cancer cells has been hypothesized to play a role, as has been suggested for g34.5-defective HSV-1. NDV also exhibits pleiotropic immune-modulatory properties 50 and induces production of double-stranded RNA, IFNs, and chemokines in infected cells. 51 The idea to use live NDV to treat cancer dates back to the 60s, when anecdotal cases of tumor regression after exposure to viral infection were observed. 52, 53 The oncolytic NDV PV701 was utilized in a phase I trial including 79 patients with various advanced solid cancers. 54 The results of this study established that optimal treatment to avoid side effects should start with low doses, followed by escalation of doses. The most common adverse events were fever and flu-like symptoms, but also serious adverse events were reported, including a treatment-related death. Another oncolytic NDV, MTH-68/H, has been investigated in phase I/II studies in patients with advanced cancer 53, 55, 56 and in 14 patients with high-grade gliomas 41 ( Table 2 ). Treatment consisted of intravenous injection of daily doses of about 2 Â 10 7 pfu of MTH-68/H. The doses were gradually increased up to 2 Â 10 8 pfu daily and, in the presence of clinical benefit, maintained during the patient's lifetime with less frequent administrations. No adverse events were reported in this study throughout the course of treatment. Of 14 patients, four patients with GBM had survival times between 5 and 9 years, including two patients who demonstrated an almost complete tumor shrinkage. 41 These results look promising, but controlled studies are needed to definitely define the safety and oncolytic activity of NDV.
Cell-mediated immunotherapy
The highly disseminated nature of malignant gliomas represents the major obstacle for effective eradication of all residual intracranial tumor reservoirs. Treatment approaches aimed at enhancing the patient's antitumor immune response, which have already demonstrated promising results in prelinical investigations and in pilot studies in humans, 57 could represent an effective adjuvant to conventional therapy to eradicate brain tumors. On the other hand, immunotherapy for malignant gliomas is a hard task, since these neoplasms are characterized by potent immunosuppressive properties, probably mediated by chemokines produced by the tumor, such as transforming growth factor beta and IL-10, that depress host antitumor immune response. 57 In fact, patients with malignant gliomas typically show lymphopenia, depressed T-cell responsiveness and antibody production and impaired antigen-presenting cell (APC) function. Moreover, glioma cells downregulate expression of major histocompatibility complex molecules, while overexpressing Fas ligand on their surface, thus inhibiting antitumor cytotoxic T lymphocyte (CTL) activity.
Cell-mediated immunotherapy strategies that have been designed for malignant brain tumors include adoptive immunotherapy and active immunotherapy (vaccination) ( Table 3) . Adoptive immunotherapy for gliomas has generally involved transfer of nonspecific lymphokineactivated killer (LAK) cells. Active immunotherapy approaches have been based on ex vivo or in vivo sensitization of patient's APCs or naive T cells to tumor-associated antigens, used as vaccines. If successful, active vaccination results not only in tumor eradication, but also in establishment of long-term immunity against tumor cells.
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Adoptive immunotherapy Several approaches of adoptive immunotherapy have been attempted (Table 3 ). Initial studies, based on intratumor or intrathecal administration of autologous immune cells, either alone 74, 75 or combined with IFN administration, 76 gave poor response. More promising results were achieved from the use of LAK cells and IL-2 injected into the surgical cavity after tumor resection, but significant toxicity was also observed, with symptoms of aseptic meningitis and increased intracranial pressure. [77] [78] [79] A complete tumor response and two partial responses, out of six treated patients, were observed after intratumor infusion of autologous tumor-infiltrating lymphocytes, expanded ex vivo in the presence of IL-2, with concurrent IL-2 infusion. 80 Tumor-infiltrating lymphocytes, however, demonstrated poor specificity and scarce antitumor activity, conceivably because of the immunosuppressed environment typical of malignant gliomas. An alternative approach to the use of autologous T-cell populations for adoptive immunotherapy was the transfer of allogeneic T cells. 81 This strategy was based on the rationale that MHC-mismatched CTLs would produce a more potent tumoricidal response against glioma cells that express MHC. This approach, however, did not confirm the encouraging preclinical results when assessed in a pilot clinical study. 82 
Active immunotherapy
Activation of an efficient antigen-specific T-cell response requires presentation of tumor antigens by professional APCs, which provide appropriate costimulatory signals. Activated T cells undergo clonal expansion with generation of CTLs, with cytotoxic activity against tumor cells and memory cells that confer long-lasting antitumor immunity. An important obstacle to the design of an efficient vaccination strategy against human malignant gliomas is represented by the fact that immunologically relevant glioma-specific antigens have not yet been identified.
Autologous tumor cell vaccination strategies. Initial vaccination strategies for glioma consisted in subcutaneous inoculation of irradiated autologous tumor cells, even engineered to produce immunostimulatory cytokines, such as IL-2 and GM-CSF. The first patient to be vaccinated for a glioblastoma received subcutaneous injections of a mixture of irradiated autologous tumor cells with fibroblasts genetically modified to secrete IL-2 by retroviral gene transfer. 83 Treatment resulted in
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Cancer Gene Therapy marked tumor necrosis and increased CTL-mediated antitumor immunity. Several vaccination studies with irradiated autologous tumor cells were performed thereafter in patients with recurrent gliomas following surgical resection of the tumor mass 58, 61 (Table 3) . In these protocols, immunogenicity of the vaccine was enhanced by mixing tumor cells with bacillus Calmette-Gue´rin and by combining vaccination with intravenous IL-2 administration and adoptive transfer of stimulated autologous T cells. Treatment was tolerated with limited toxicity and some patients demonstrated partial response. Moreover, development of delayed-type hypersensitivity occurred in all patients. 58, 61 A similar vaccination strategy was pursued by Plautz et al., 59 ,60 who added GM-CSF to the vaccine preparation, instead of BCG, and used as immune effector cells lymphocytes obtained from lymph nodes draining the vaccination site and cultured with staphylococcal enterotoxin A, anti-CD3, and low doses of IL-2. Also, this vaccination protocol was safe and, in some cases, led to partial tumor regression. 59, 60 Preliminary data of safety and efficacy have been also reported with an autologous glioma cell vaccine admixed with IL-4 gene-transfected fibroblasts. 84 An interesting vaccination strategy employed antisense oligodeoxynucleotides to inhibit expression of the type I insulin growth factor receptor (IGF-IR) in cultured glioma cells. The rationale for this approach was based on the observation that inhibition of IGF-IR in experimental glioma models results in massive apoptosis of tumor cells, marked inhibition of tumorigenesis and metastasis, and stimulation of an immune response against cancer cells.
85, 86 The clinical study was performed in 12 patients operated for recurrent GBM or anaplastic astrocytoma, who were vaccinated by implantation into the rectus sheath of irradiated autologous glioma cells encapsulated in diffusion chambers, after incubation with IGF-IR antisense oligodeoxynucleotides. 62 Treatment was associated with a rather high incidence of deep vein thrombosis, so that anticoagulant prophylaxis was included in the protocol, but also with a relatively high rate of clinical and radiological improvements. Interestingly, histological analysis of tumors resected from patients with disease progression revealed necrosis, lymphocytic infiltration, and microvessel thrombosis. 62 The immune-modulatory properties of NDV have been exploited as adjuvants to increase the immunogenicity of cultured autologous glioblastoma cells in pilot and phase I studies 63, 64 (Table 3) . After vaccination with autologous tumor cells cultured in vitro and infected with NDV, the patients showed activation of specific CTL and memory antitumor immune responses and the presence of CD8 þ cytotoxic tumor-infiltrating lymphocytes, but not after administration of inactivated tumor cells alone. 63, 64 One of the patients demonstrated objective tumor remission after vaccination and, altogether, patients had a significantly longer progression-free survival and overall survival than a nonrandomized matched group of GBM patients treated only by surgery and radiotherapy. 64 Dendritic cell vaccinations. Taken together, the vaccination protocols based on autologous tumor cells have given promising results, notwithstanding the well-known poor antigen-presenting capacity of glioma cells. To induce a more efficient and specific immune response against malignant gliomas, professional APCs, such as dendritic cells (DCs), have been used. 87 DCs, characterized by high expression of costimulatory molecules, are present in peripheral tissues, where they efficiently capture antigens. As DCs move towards the draining secondary lymphoid organs, they process and present antigens to naive T cells, thereby inducing a cellular immune response that involves both CD4 þ T-helper cells and CD8 þ CTLs. DCs can also activate NK cells and induce humoral immunity by activation of naive and memory B cells. 88 In vaccination studies against gliomas (Table 3) , DCs are obtained from peripheral blood stem cells of patients and pulsed either with peptides eluted from the surface of cultured autologous brain tumor cells 65, 66 or with autologous tumor lysates. 67, 69, 70, 89 DCs have been also fused with autologous glioma cells to generate vaccines. 71, 72 Vaccination with DCs pulsed with autologous tumor peptides or autologous tumor lysates has been performed in a total of 70 patients with malignant glioma (Table 3) . Treatment has been shown to be safe and to enhance peripheral tumor-reactive CTL activity, and to significantly increase the number of tumor-infiltrating lymphocytes. 65 Although the number of objective tumor responses was low, the association of vaccination with chemotherapy seemed to significantly prolong the progression-free and overall survival times as compared with each treatment alone 66 or with historical controls. 68 With respect to the preparation of peptide-pulsed DCs, which is a long and laborious procedure, preparation of DCs stimulated by autologous tumor lysates is more easy and does not require previous identification of tumorassociated antigens. Tumor-lysate pulsed DCs have been also safely employed for intradermal and intratumor vaccination in patients with recurrent gliomas. 67, 70 The idea of injecting DCs intratumorally aims at promoting the processing of tumor antigens in situ and at initiating tumor-specific immune response in local lymphoid organs. 90 In one protocol, intratumor administration of immature DCs was combined with intradermal vaccinations with mature DCs, differentiated with the streptococcal preparation OK-432 73 (Table 3) . It was demonstrated the GBM patients receiving matured DCs experienced longer survival than patients without OK-432 maturation, and that the GBM patients with both intratumoral and intradermal administration had longer overall survival times than the patients with intradermal administration. 70 DCs have been also fused with cultured autologous glioma cells and injected intradermally for the treatment of patients with malignant glioma. 71, 72 Also, this vaccination protocol was not associated with any serious adverse effect and induced antitumor immune responses and partial regression of the tumor mass in some cases. 71 
Subcutaneous injection of recombinant human IL-12 at
Cell and gene therapy for malignant gliomas L Barzon et al the same site after vaccination was safe and seemed to be associated with a higher tumor response rate. 72 
Concluding remarks
Several pilot and phase I/II clinical studies of gene therapy, virotherapy, and active immunization for malignant gliomas have been undertaken and results are now available. If the feasibility and safety of the different therapeutic modalities have been sufficiently documented, efficacy has not yet been convincingly proven, despite reports of improved survival of patients and objective tumor responses. Indeed, the only phase III randomized multicenter clinical protocol of the evaulation of efficacy of retroviral vector-mediated HSV-TK suicide gene therapy for GBM failed to demonstrate the superiority of gene therapy over conventional therapy. Thus, welldesigned phase II and phase III trials are urgently needed to assess the efficacy of the other promising gene therapy approaches, such as adenoviral vector-mediated delivery of suicide genes or the delivery of combinations of suicide and cytokine genes. It is becoming more and more evident from clinical studies on conventional chemotherapy and radiotherapy that multi-modality treatment strategies have a higher chance of success, conceivably because they simultaneously hit different tumor targets. This paradigm is true also for gene therapy. Indeed, a poly-gene therapy approach, including delivery of suicide, cytokine, and antiangiogenic genes, should have a higher chance to knock down all the molecular alterations that accumulate during tumor formation, whereas a combination of different immunotherapeutic strategies should prevent the risk that tumor cells evade immune clearance.
Perhaps, the most promising results have been achieved from pilot studies with oncolytic viruses, but, even in this case, a long way still has to be gone before finding the best oncolytic virus with optimal safety and therapeutic requirements. Again, reports from clinical trials of viral oncolysis for other types of malignancies teach us that virotherapy is more effective when combined with other therapeutic modalities, such as chemotherapy and radiotherapy.
As for active immunotherapy, vaccination with primed DCs seems to be superior to conventional vaccination with inactivated autologous tumor cells, and, besides intradermal DC administration, intratumor injection of immature DCs seems to be also effective. DC vaccination protocols for gliomas, however, still need to be optimized, regarding, for example, the type of antigen for priming, the method for antigen loading, the route of delivery, etc.
Thus, in a scenario that remains gloomy for patients with malignant gliomas, notwithstanding advances in radiation therapy, chemotherapy, and surgical techniques, hope still relies on the promises of these new molecular therapies. Success will probably come with the application of global investigation strategies to dissect the mechanisms at the basis of cancer and to identify new molecular targets for vaccination, gene delivery, or virotherapy. But, even in this horizon, in order to be effective and contribute to the improvement of patient's outcome, gene therapy and vaccination will have to play an adjuvant role to conventional treatment modalities. This is what the most recent gene therapy and vaccination clinical trials have taught us.
